| Attribute |
Value |
| 52 Week Change |
0.78458154 |
| Address1 |
Building 23 |
| Address2 |
Suite 105 221 Crescent Street |
| All Time High |
449.75 |
| All Time Low |
2.01 |
| Ask |
25.71 |
| Ask Size |
2 |
| Audit Risk |
7 |
| Average Analyst Rating |
1.1 - Strong Buy |
| Average Daily Volume10 Day |
518,180 |
| Average Daily Volume3 Month |
532,787 |
| Average Volume |
532,787 |
| Average Volume10Days |
518,180 |
| Beta |
1.435 |
| Bid |
14.47 |
| Bid Size |
2 |
| Board Risk |
7 |
| Book Value |
6.254 |
| City |
Waltham |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
8 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
19.035 |
| Current Ratio |
19.731 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
20.28 |
| Day Low |
18.93 |
| Display Name |
Damora Therapeutics |
| Dividend Yield |
0.0 |
| Earnings Timestamp End |
1,793,908,800 |
| Earnings Timestamp Start |
1,793,908,800 |
| Ebitda |
-96,325,000 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-8.72 |
| Enterprise Value |
839,934,912 |
| Eps Current Year |
-1.895 |
| Eps Forward |
-2.1725 |
| Eps Trailing Twelve Months |
-0.25 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
26.3469 |
| Fifty Day Average Change |
-7.311901 |
| Fifty Day Average Change Percent |
-0.27752414 |
| Fifty Two Week Change Percent |
78.45815 |
| Fifty Two Week High |
38.325 |
| Fifty Two Week High Change |
-19.29 |
| Fifty Two Week High Change Percent |
-0.50332683 |
| Fifty Two Week Low |
4.95 |
| Fifty Two Week Low Change |
14.085 |
| Fifty Two Week Low Change Percent |
2.8454547 |
| Fifty Two Week Range |
4.95 - 38.325 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,603,978,200,000 |
| Float Shares |
40,886,817 |
| Forward Eps |
-2.1725 |
| Forward P E |
-8.761795 |
| Free Cashflow |
-15,979,875 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
7 |
| Fullday Change |
-1.2199993 |
| Fullday Change Percent |
-6.023201 |
| Fullday Price |
19.035 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,790,812,800 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.084309995 |
| Held Percent Institutions |
1.0603299 |
| Implied Shares Outstanding |
61,735,519 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,724,976,000 |
| Last Split Factor |
1:25 |
| Long Business Summary |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. |
| Long Name |
Damora Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
1,175,135,616 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_154090027 |
| Most Recent Quarter |
1,782,777,600 |
| Name Change Date |
2,026-10-13 |
| Net Income To Common |
-241,250,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
1,263,571,735 |
| Number Of Analyst Opinions |
9 |
| Open |
20.09 |
| Operating Cashflow |
-44,515,000 |
| Operating Margins |
0.0 |
| Overall Risk |
8 |
| Phone |
781 281 9020 |
| Prev Name |
Galecto, Inc. |
| Previous Close |
20.255 |
| Price Eps Current Year |
-10.044855 |
| Price Hint |
2 |
| Price To Book |
3.043652 |
| Profit Margins |
0.0 |
| Quick Ratio |
19.651 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.1 |
| Region |
US |
| Regular Market Change |
-1.2199993 |
| Regular Market Change Percent |
-6.023201 |
| Regular Market Day High |
20.28 |
| Regular Market Day Low |
18.93 |
| Regular Market Day Range |
18.93 - 20.28 |
| Regular Market Open |
20.09 |
| Regular Market Previous Close |
20.255 |
| Regular Market Price |
19.035 |
| Regular Market Time |
1,791,912,723 |
| Regular Market Volume |
113,012 |
| Return On Assets |
-0.21609 |
| Return On Equity |
-0.99741995 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
8 |
| Shares Outstanding |
61,735,519 |
| Shares Percent Shares Out |
0.0767 |
| Shares Short |
4,733,297 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
4,131,367 |
| Short Name |
Damora Therapeutics, Inc. |
| Short Percent Of Float |
0.089499995 |
| Short Ratio |
6.09 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
DMRA |
| Target High Price |
60.0 |
| Target Low Price |
40.0 |
| Target Mean Price |
46.88889 |
| Target Median Price |
45.0 |
| Total Cash |
540,515,008 |
| Total Cash Per Share |
8.755 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.25 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
25.899124 |
| Two Hundred Day Average Change |
-6.8641243 |
| Two Hundred Day Average Change Percent |
-0.26503307 |
| Type Disp |
Equity |
| Volume |
113,012 |
| Website |
https://www.damoratx.com |
| Zip |
2,453 |